Isoniazid’s Mechanism in Mycobacterial Cell Wall Synthesis

Isoniazid kills Mycobacterium tuberculosis by shutting down the production of mycolic acids, the unusually long-chain fatty acids that form the backbone of the mycobacterial outer membrane. It does not accomplish this on its own. Isoniazid is a prodrug that must be chemically activated inside the bacterial cell before it can strike its target, an enzyme called InhA that sits at the heart of the mycolic acid assembly line. The result of that strike is a bacterium whose protective envelope falls apart, leading to cell death. But the path from swallowed pill to collapsed cell wall involves a surprising number of molecular handoffs, and each one turns out to matter for understanding why the drug works, why it sometimes fails, and why it is so narrowly selective.

Why the Mycobacterial Cell Wall Is Special

Most bacteria have some kind of outer barrier, but mycobacteria take it to an extreme. The cell wall of M. tuberculosis is built around a covalently linked skeleton made of peptidoglycan, a branched sugar polymer called arabinogalactan, and mycolic acids. Arabinogalactan connects the inner peptidoglycan layer to the outer mycolic acid layer, forming what researchers call the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex.¹ The mycolic acids themselves are the inner leaflet of an unusual outer membrane, sometimes called the mycomembrane, whose outer leaflet is made up of various free-floating lipids and glycolipids.²

This elaborate, waxy barrier is what makes tuberculosis so hard to treat. It blocks many antibiotics from entering, shields the bacterium from the host immune system, and contributes to the organism’s slow growth and ability to persist inside human cells for decades. Mycolic acids are essential for survival; without them the entire envelope loses structural integrity.³ That essentiality is precisely what makes the mycolic acid biosynthesis pathway such a valuable drug target.

Activation by KatG

Isoniazid as it comes out of the bottle is pharmacologically inert. It becomes lethal only after being activated inside the mycobacterial cell by an enzyme called KatG, a catalase-peroxidase that the bacterium normally uses to neutralize hydrogen peroxide and other reactive oxygen species.⁴ KatG oxidizes isoniazid into a reactive radical, and that radical then does something critical: it latches onto NAD+, a coenzyme the cell uses in countless metabolic reactions, to form a new molecule called the INH-NAD adduct.⁵

This two-step activation makes isoniazid unusual among antibiotics. Most drugs arrive at their target ready to work. Isoniazid depends entirely on the bacterium’s own enzyme to convert it into an active weapon. The consequence is that the drug’s potency is inseparable from how efficiently KatG performs that conversion, a point that becomes important when we look at drug resistance.

The INH-NAD Adduct and Its Target

The INH-NAD adduct is the actual killer molecule. It binds to InhA, a NADH-dependent enoyl-ACP reductase that is one of several enzymes in the type II fatty acid synthase (FAS-II) system responsible for elongating fatty acid chains into mycolic acids.⁶ The FAS-II system has the unusual job of producing very-long-chain fatty acids, and InhA catalyzes a reduction step that is needed in every cycle of chain elongation.⁷

Structural studies show that the INH-NAD adduct physically displaces the normal NADH cofactor from InhA’s active site and locks the enzyme in an inactive state.⁸ The binding is slow and tight, meaning the adduct does not just bump into InhA and bounce off; it wedges in and stays, effectively removing InhA from the cell’s metabolic toolkit for good.⁵ Research also indicates that activated isoniazid can form adducts with NADP+ as well, potentially hitting other enzymes that depend on pyridine nucleotide coenzymes, though InhA remains the primary and best-validated target.⁹

What Happens When Mycolic Acid Synthesis Stops

When InhA is inhibited, the downstream consequences unfold quickly. The bacterium can no longer produce normal mycolic acids, and the mAGP complex at the core of its cell wall starts to lose integrity. Studies in which researchers conditionally depleted InhA found that the loss led to inhibition of key mycolic acid classes and, ultimately, to cell lysis. Scanning electron micrographs showed characteristic blebbing on the cell surface before the cells fell apart, a pattern distinct from the “crumpled” appearance seen when a different FAS-II enzyme, KasA, was depleted instead.¹⁰

The blebbing pattern is a visual clue to what is happening at the molecular level: the outer membrane loses its structural foundation, bulges outward, and eventually ruptures. The cell effectively comes apart because its armor has been dismantled from the inside. This is why isoniazid is bactericidal rather than merely bacteriostatic against actively growing M. tuberculosis. It does not just slow the bacteria down; it destroys the structure they depend on for survival.

Why Isoniazid Is So Narrow in Its Spectrum

One of the more puzzling features of isoniazid is how selective it is. It devastates M. tuberculosis but is far less effective against many other mycobacteria, and essentially useless against non-mycobacterial species. The reason traces back to the activation step. Biophysical and biochemical testing of KatG proteins from different mycobacterial species showed that the KatG enzymes of nontuberculous mycobacteria like M. marinum and M. avium have lower affinity for isoniazid and are substantially less effective at converting it into its active form.¹¹

In other words, the drug’s narrow spectrum is not about the target enzyme differing across species. InhA homologs exist throughout the bacterial world. The selectivity comes almost entirely from how well each species’ KatG can light the fuse. M. tuberculosis happens to have a KatG that is exceptionally good at activating isoniazid, which is both the drug’s greatest strength and, as we will see, its Achilles’ heel.

How Resistance Develops

Because the drug’s killing power depends on a chain of molecular events, resistance can emerge at several links in that chain. The most common route, by a wide margin, involves mutations in the katG gene itself. The single most frequently identified mutation is S315T, where a serine at position 315 is replaced by threonine. This substitution preserves enough catalase-peroxidase activity for the bacterium to survive oxidative stress while reducing its ability to activate isoniazid, resulting in clinically significant resistance.¹²

A large systematic review of isoniazid resistance mutations found that position 315 of katG remained the most commonly mutated locus by far, with thousands of documented cases, followed by mutations in the promoter region of the inhA gene at positions -15 and -8.¹³ Promoter mutations in inhA work differently from katG mutations: rather than blocking drug activation, they cause the bacterium to overproduce InhA protein, overwhelming the amount of INH-NAD adduct available. There is simply too much target for the drug to knock out.

Structural studies of InhA mutants found in resistant clinical isolates, such as the I21V and S94A variants, have helped clarify how subtle changes in the enzyme’s shape can weaken adduct binding without destroying the enzyme’s normal function.¹⁴ In practice, though, target-site mutations in inhA itself are less common than either katG mutations or inhA promoter mutations. Additional genes, including ethA, ndh, and mshA, have also been linked to isoniazid resistance in various contexts.¹⁵

The Ethionamide Connection

Ethionamide is a second-line tuberculosis drug that is structurally related to isoniazid, and it turns out the two drugs converge on exactly the same target. Both ultimately inhibit InhA to block mycolic acid synthesis. The difference is in how they get activated. While isoniazid requires KatG, ethionamide depends on a different enzyme, a monooxygenase called EthA. Once activated, each drug forms its own adduct with NAD+ that plugs into InhA’s active site and shuts it down.¹⁶

This shared target creates a clinically important pattern of cross-resistance. Early work showed that a missense mutation in the inhA gene could confer resistance to both isoniazid and ethionamide simultaneously.¹⁷ The clinical implication is straightforward: if a patient’s TB strain has an inhA promoter mutation, ethionamide may not be a reliable fallback drug. On the other hand, strains with katG mutations that knock out only the isoniazid activation step may remain fully susceptible to ethionamide, since ethionamide takes its own separate activation route through EthA. This distinction matters for selecting treatment regimens.

Beyond the Cell Wall: Reactive Oxygen Species

Although InhA inhibition and mycolic acid disruption are the primary killing mechanism, the activation of isoniazid by KatG also generates reactive intermediates. These toxic byproducts create oxidative stress inside the bacterial cell, and some evidence suggests that this oxidative damage contributes to isoniazid’s bactericidal effect on top of the cell-wall disruption. Research on the iron-dependent regulator IdeR in Mycobacterium smegmatis found that this protein has a protective role against both reactive oxygen species and isoniazid-derived toxic intermediates, suggesting that the drug’s activation unleashes a secondary wave of cellular stress.¹⁸

How much this oxidative stress matters relative to the direct InhA inhibition is still debated. Researchers studying the INH-NAD(P) adducts have identified multiple binding partners beyond InhA across the proteome, hinting at a broader disruption of the cell’s metabolic network.⁹ But InhA remains the validated primary target, and the simplest summary is that isoniazid’s lethality comes mainly from destroying the cell wall, with oxidative damage as a supporting player.

How the Human Body Handles Isoniazid

The drug’s mechanism inside the bacterium is only half the pharmacological story. Once isoniazid enters the human body, it is metabolized primarily by the liver enzyme N-acetyltransferase 2 (NAT2), which acetylates the drug and inactivates it. People inherit different variants of the NAT2 gene, and those variants fall into three broad categories: slow acetylators, intermediate acetylators, and fast acetylators. The practical difference is large. In a study of tuberculosis patients, slow acetylators had median two-hour isoniazid plasma concentrations roughly two and a half times higher than fast acetylators.¹⁹ Another study in southern Thailand reported even more dramatic spreads, with fast acetylators showing median levels well under 1 µg/mL while slow acetylators exceeded 4 µg/mL.²⁰

These differences have real consequences. Fast acetylators clear the drug quickly and may not maintain adequate concentrations long enough to kill all the bacteria, potentially increasing the risk of treatment failure or resistance. Slow acetylators keep the drug in their system longer, which improves bacterial killing but raises the risk of liver toxicity, the most feared side effect of isoniazid therapy. The frequency of these acetylator types varies across populations: slow acetylation is more common in some European and Middle Eastern populations, while fast acetylation predominates in parts of East Asia. In principle, genotype-guided dosing could optimize the balance between efficacy and safety, though routine NAT2 testing before starting isoniazid is not yet standard practice in most settings.

Direct InhA Inhibitors and the Future

The fact that most isoniazid resistance stems from katG mutations rather than changes in the InhA target itself has prompted a straightforward question: what if you could inhibit InhA directly, bypassing the need for KatG activation altogether? Researchers have been pursuing this idea for years, and a class of compounds called 4-hydroxy-2-pyridones has emerged as a leading candidate. In laboratory testing, these direct InhA inhibitors (DIIs) retained full activity against multidrug-resistant clinical isolates carrying katG mutations, precisely because they do not need KatG to work.²¹

More recent work has tested specific DIIs, including compounds designated GSK693 and GSK138, in animal models of tuberculosis. These compounds showed a clear distinction from isoniazid in their activity against isoniazid-resistant strains and contributed meaningfully to novel drug combinations, suggesting they could serve as partners in future regimens designed for resistant TB.²² If any of these compounds make it through clinical trials, they would represent a rare feat in antibiotic development: taking a validated target that resistance has partly shielded from an existing drug and finding a new way in. The target, InhA, remains as essential to the bacterium as it ever was. It is the lock-and-key mechanism of the old drug that resistance has outmaneuvered, not the vulnerability of the target itself.

Rapid Phenotypic Testing and Drug Susceptibility

Understanding isoniazid’s mechanism also matters for diagnosis. Molecular tests can look for specific katG or inhA promoter mutations to predict resistance, but genotype does not always perfectly predict phenotype, especially when rarer mutations are involved. Phenotypic drug susceptibility testing, where you expose live bacteria to the drug and see if they grow, remains the gold standard. Traditionally this has been painfully slow because M. tuberculosis divides only once every 18 to 24 hours. Recent experimental approaches have managed to detect growth differences between isoniazid-treated and untreated mycobacterial populations in under three hours, a fraction of a single generation time, by using highly sensitive measurement techniques.²³ If methods like these mature into clinical tools, they could dramatically speed up the process of determining whether a patient’s TB strain will respond to isoniazid, a question that currently can take weeks to answer definitively.